540 related articles for article (PubMed ID: 16198399)
21. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.
Triller N; Korosec P; Kern I; Kosnik M; Debeljak A
Lung Cancer; 2006 Nov; 54(2):235-40. PubMed ID: 16934363
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
Allal AS; Waelchli L; Bründler MA
Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
25. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
27. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.
Penson RT; Oliva E; Skates SJ; Glyptis T; Fuller AF; Goodman A; Seiden MV
Gynecol Oncol; 2004 Apr; 93(1):98-106. PubMed ID: 15047220
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer.
Marx D; Binder C; Meden H; Lenthe T; Ziemek T; Hiddemann T; Kuhn W; Schauer A
Anticancer Res; 1997; 17(3C):2233-40. PubMed ID: 9216694
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary.
Terauchi F; Okamoto A; Nagashima T; Kobayashi Y; Moritake T; Yamamoto Y; Takakura S; Iwaki S; Ogura H
Oncol Rep; 2005 Aug; 14(2):363-8. PubMed ID: 16012716
[TBL] [Abstract][Full Text] [Related]
31. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma.
Herod JJ; Eliopoulos AG; Warwick J; Niedobitek G; Young LS; Kerr DJ
Cancer Res; 1996 May; 56(9):2178-84. PubMed ID: 8616869
[TBL] [Abstract][Full Text] [Related]
34. Expression and prognostic value of the lung resistance-related protein (LRP) in germ cell testicular tumors.
Mándoky L; Géczi L; Doleschall Z; Bodrogi I; Csuka O; Kásler M; Bak M
Anticancer Res; 2004; 24(2C):1097-104. PubMed ID: 15154630
[TBL] [Abstract][Full Text] [Related]
35. Expression of lung resistance-related protein in transitional cell carcinoma of bladder.
Zhu Y; Kong C; Zeng Y; Sun Z; Gao H
Urology; 2004 Apr; 63(4):694-8. PubMed ID: 15072883
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
Brustmann H; Naudé S
Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
39. Ovarian serous carcinoma: relationship of p53 and bcl-2 with tumor angiogenesis and VEGF expression.
Crasta JA; Mishra S; Vallikad E
Int J Gynecol Pathol; 2011 Nov; 30(6):521-6. PubMed ID: 21979585
[TBL] [Abstract][Full Text] [Related]
40. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.
Arts HJ; Katsaros D; de Vries EG; Massobrio M; Genta F; Danese S; Arisio R; Scheper RJ; Kool M; Scheffer GL; Willemse PH; van der Zee AG; Suurmeijer AJ
Clin Cancer Res; 1999 Oct; 5(10):2798-805. PubMed ID: 10537344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]